Medication info
Piovis Tablets 15/850 mg

Piovis Tablets 15/850 mg

Prescription medicationTablet
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletPioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
International Pharmaceutical Co., Ltd.
Appearance
White to grayish-white oblong film-coated tablet
Packaging
30 tablets (10 tablets/PTP*3)
Approval status
Active

MFDS item code 201804719 · Approved 2018.11.28 · Insurance code 643704650

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the patient's current dose of metformin or pioglitazone. Start with 1 tablet of this drug daily, and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their previous doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. After this drug is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an adequate period (8-12 weeks) to assess changes in HbA1C is recommended.

Ingredients

Manufacturer
International Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Insulin-independent diabetes
  • blood sugar control disorders
  • type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control for patients with insulin-independent diabetes, namely type 2 diabetes. It is particularly administered when blood sugar control is insufficient with monotherapy of either Metformin or Pioglitazone and can also be used instead of combination therapy with both medications. Management of type 2 diabetes is critical and involves dietary and exercise therapy, and weight loss along with nutritional counseling is also necessary. Such lifestyle improvements are essential not only for initial treatment but also for maintaining the effectiveness of medication therapy. This medication helps in improving blood sugar control alongside these treatments.

Dosage and Administration

Adult dosage

For the treatment of patients with type 2 diabetes mellitus, the dose of this drug should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the patient's current dose of metformin or pioglitazone. Start with 1 tablet of this drug daily, and gradually adjust the dose after assessing the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this drug may start at their previous doses of pioglitazone and metformin. No studies have been conducted to evaluate the safety and efficacy of switching from another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this drug. After this drug is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This drug should generally be administered in divided doses with meals to reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the response to treatment should be assessed using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the past 2 - 3 months. In clinical use of this drug, if glycemic control measured by FPG has not worsened, administration for an adequate period (8-12 weeks) to assess changes in HbA1C is recommended.

Precautions

This medication is used to control blood sugar and consists of two main ingredients. The first ingredient is Metformin, which helps utilize sugars effectively in the body and lowers blood sugar levels. However, this ingredient can rarely cause lactic acidosis, a serious metabolic problem where lactic acid accumulates excessively in the body, leading to a dangerous state. Lactic acidosis is more likely to occur in patients with impaired renal function, heart or lung issues, and in cases of infections or dehydration, so caution is required. Moreover, the use of this medication should be avoided in patients with liver dysfunction or those consuming excessive alcohol. The second ingredient is Pioglitazone, which aids insulin action and helps control blood sugar. However, this ingredient can exacerbate or newly induce heart failure, so patients with severe or symptomatic heart diseases should not use this medication. Additionally, this medication can cause fluid retention, leading to edema or weight gain, necessitating careful monitoring for symptoms of heart failure. This medication should not be administered to patients with impaired renal function, severe heart failure, active bladder cancer, pregnant or breastfeeding women, and certain genetic lactase deficiency disorders. Regular kidney function tests and liver function tests are recommended during medication use, as well as periodic checks for vitamin B12 levels. Furthermore, due to the risk of hypoglycemia, patients with irregular eating patterns, engaging in strenuous exercise, or those using other hypoglycemic agents should exercise increased caution. If symptoms such as sudden shortness of breath, muscle pain, weakness, or abdominal pain occur during administration, the physician should be notified immediately. Finally, this medication should be discontinued for a certain period before and after surgery or before tests that involve iodinated contrast agents. It is also safer to avoid excessive alcohol consumption. Patients and caregivers should thoroughly understand these precautions, and any abnormal symptoms during medication use should be promptly reported to healthcare personnel.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • fatigue
  • myalgia
  • dyspnea
  • weakness
  • abdominal pain
  • hypothermia
  • hypotension
  • resistant bradyarrhythmia
Show 34 more
  • upper respiratory infection
  • diarrhea
  • complex edema
  • peripheral edema
  • headache
  • nausea
  • urinary tract infection
  • sinusitis
  • dizziness
  • lower limb edema
  • weight gain
  • myalgia
  • dental disorders
  • worsening diabetes
  • pharyngitis
  • anemia
  • reduced vision
  • diabetic macular edema
  • liver failure
  • congestive heart failure
  • edema
  • weight gain
  • dyspepsia
  • insomnia
  • dry mouth
  • constipation
  • abdominal distension
  • gastroesophageal reflux disease
  • intestinal gas retention
  • increased serum creatinine
  • increased serum urea
  • fracture
  • abnormal blood sugar
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White to grayish-white oblong film-coated tablet

Package unit

30 tablets (10 tablets/PTP*3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.